MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Takeda Pharmaceutical Co Ltd ADR

Suletud

SektorTervishoid

15.19 1.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.97

Max

15.34

Põhinäitajad

By Trading Economics

Sissetulek

-68B

24B

Müük

-32B

1.1T

P/E

Sektori keskmine

34.581

63.778

Aktsiakasum

0.048

Dividenditootlus

4.39

Kasumimarginaal

2.079

Töötajad

49,281

EBITDA

-4.3B

380B

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.39%

2.39%

Turustatistika

By TradingEconomics

Turukapital

47B

Eelmine avamishind

13.72

Eelmine sulgemishind

15.19

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. jaan 2025, 11:02 UTC

Tulu

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30. jaan 2025, 07:53 UTC

Tulu

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

28. jaan 2025, 00:03 UTC

Kuumad aktsiad

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

31. okt 2024, 07:27 UTC

Tulu

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

31. okt 2024, 06:44 UTC

Tulu

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

31. juuli 2024, 07:19 UTC

Tulu

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

31. juuli 2024, 06:29 UTC

Tulu

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

17. juuni 2024, 13:34 UTC

Suurimad hinnamuutused turgudel

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

13. mai 2024, 11:26 UTC

Suurimad hinnamuutused turgudel

AC Immunity Shares Soar on Exclusive License Deal with Takeda

9. mai 2024, 07:37 UTC

Tulu

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

9. mai 2024, 07:08 UTC

Tulu

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

30. jaan 2025, 07:12 UTC

Tulu

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30. jaan 2025, 07:08 UTC

Tulu

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30. jaan 2025, 06:42 UTC

Tulu

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30. jaan 2025, 06:40 UTC

Tulu

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30. jaan 2025, 06:36 UTC

Tulu

Takeda: to Discontinue Soticlestat Development Program

30. jaan 2025, 06:34 UTC

Tulu

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30. jaan 2025, 06:32 UTC

Tulu

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30. jaan 2025, 06:31 UTC

Tulu

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical Sees FY Net Y118.00B

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical Sees FY Net Y118.00B

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

30. jaan 2025, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Võrdlus sarnastega

Hinnamuutus

Takeda Pharmaceutical Co Ltd ADR Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

14.89 / 15.155Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.